Premium
P3‐331: Methylene blue reduced tau phosphorylation and aggregation in P301L tau transgenic mice
Author(s) -
Hosokawa Masato,
Arai Tetsuaki,
aka Takashi,
Yamashita Makiko,
Suzukake Masami,
Hasegawa Masato,
Akiyama Haruhiko
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.1555
Subject(s) - methylene blue , western blot , intracellular , in vivo , methylene , phosphorylation , genetically modified mouse , microbiology and biotechnology , transgene , blot , chemistry , tau protein , biology , medicine , biochemistry , medicinal chemistry , gene , genetics , photocatalysis , catalysis , disease , alzheimer's disease
facturer’s protocol for each antibody. Proteins were either detected on x-ray film using enhanced chemiluminscent reagents from Pierce, or detected via the LICOR Odyssey infrared imaging system with secondary antibodies sensitive to 685 and 785 excitation wavelengths. Results: Significant increase in synapsin and spinophilin expression in melatonin-treated AD animals as compared to samples from AD mice not treated. Phosphorylated MAP2 as well as phospho-tau is significantly lower in melatonin-treated AD mouse brain. Conclusions: These findings add to the growing body of evidence that melatonin serves to protect the AD brain through a variety of target cell responses.